Healthcare Stocks Biotech Stocks Growth Stocks Life Sciences

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

After several years of advancing DMX-200/Qytovra, Dimerix is entering the most consequential chapter of its life. The upcoming blinded statistical powering analysis for ACTION3 is the moment where all of…

ByNick Sundich

15

Jan 2026

Healthcare Stocks

5 ASX Healthcare Companies with Game Changing Milestones in 2026!

2026 is set to be a big year for several ASX Healthcare Companies, especially companies in the pre-commercialisation stage. The two keys to get drugs or devices to market are…

ByNick Sundich

01

Dec 2025

Uncategorized

Dimerix (ASX:DXB) gets ready for game day

Our sister company Pitt Street Research published a research update on the Melbourne-based drug developer Dimerix (ASX: DXB). Pitt Street Research used to have a valuation range of between 84…

ByStuart Roberts

21

Oct 2025

Healthcare Stocks

There’s a US$180bn Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps

There's a Biotech Patent Cliff coming over the next decade! Investors aren't giving this much attention, but we think they should because it could cause substantial upheaval in the biotech…

ByNick Sundich

27

Aug 2025

Healthcare Stocks Life Sciences

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Here are 5 ASX biotechs expecting clinical trial results in the next few months! Dimerix (ASX:DXB) Dimerix is in the middle of a Phase III trial or its DMX-200 drug…

ByNick Sundich

01

May 2025

Biotech Stocks Healthcare Stocks

Kidney disease-focused biotech Dimerix announced a US licensing deal for DMX-200! And this could be the best deal of all!

Dimerix has been targeting a US licensing deal for DMX-200 and the dreams are now a reality as of this morning! The company already had licensing deals with 2 companies…

ByNick Sundich

10

Jan 2025

Healthcare Stocks Life Sciences

The Top ASX Health Stocks for 2025: Here Are Our 5 Picks!

Here Are Our 5 Top ASX Health Stocks for 2025! Avita Medical (ASX:AVH) OK, first thing's first. We know this ASX health stock fell 14% on January 8 after…

ByNick Sundich

27

Nov 2024

Healthcare Stocks

Dimerix (ASX:DXB): This exciting Phase 3 biotech could be about to follow in the footsteps of Telix and Neuren

Dimerix (ASX:DXB) is one of the few ASX biotechs in the middle of a Phase 3 trial, and it even has data showing the trial is a success. After years…

ByNick Sundich

23

Aug 2024

Healthcare Stocks

Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval

The list of major milestones of ASX biotech companies is headed with clinical trial results, regulatory approval and commercialisation. However, clinical trials can take a long time, and there are…

ByNick Sundich

16

Aug 2024

Bank Stocks Basic Materials Blue Chip Stocks Cannabis Stocks Consumer Defence Stocks Education Energy Stocks General Index Funds Industrials Large Caps Market news Mining Stocks News Real Estate Resources Tech Stocks Technology Travel Stocks

6 of the best performing ASX All Ords stocks in the past year

6 of the best performing ASX All Ords stocks in the past year Clarity Pharmaceuticals (ASX:CU6) Clarity is a late-stage clinical biotech, testing its Targeted Copper Theranostics (TCT) technology in…

ByNick Sundich

Dimerix And Its DMX-200 (Qytovra) Therapy Approach Their Most Important Catalyst

5 ASX Healthcare Companies with Game Changing Milestones in 2026!

Dimerix (ASX:DXB) gets ready for game day

There’s a US$180bn Biotech Patent Cliff coming! Here’s why it could spell doom for large caps, but a generational opportunity for small caps

Here are 5 ASX biotechs expecting clinical trial results in the next few months!

Kidney disease-focused biotech Dimerix announced a US licensing deal for DMX-200! And this could be the best deal of all!

The Top ASX Health Stocks for 2025: Here Are Our 5 Picks!

Dimerix (ASX:DXB): This exciting Phase 3 biotech could be about to follow in the footsteps of Telix and Neuren

Here are 6 important milestones of ASX biotech companies other than clinical trial results and regulatory approval

6 of the best performing ASX All Ords stocks in the past year

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Add Your Heading Text Here